Dalotuzumab
Clinical Trials Overview
3 trials found
About Dalotuzumab
Dalotuzumab (MK-0646) is a humanized monoclonal antibody that targets the insulin-like growth factor-1 receptor (IGF-1R) pathway. This targeted therapy has been evaluated in metastatic colorectal cancer, particularly in combination with established treatments like cetuximab and irinotecan. The drug was developed to block IGF-1R signaling, which promotes tumor cell growth and survival in various cancer types including colorectal cancer.
Category
Immunotherapy
Brand Name
Not yet branded
Mechanism
Dalotuzumab binds specifically to the insulin-like growth factor-1 receptor (IGF-1R), blocking the binding of IGF-1 and IGF-2 ligands to this receptor. This inhibition disrupts downstream signaling pathways including PI3K/AKT and MAPK pathways, which are critical for cancer cell proliferation, survival, and metastasis.
3
Total Trials
0
Recruiting
0
Active
3
Completed
616
Total Enrollment
0
Countries
med_trials_trend_title
Number of trials started per year
med_trials_trend_flat
Phase:
NCT01609231
Phase 2
Completed
11 patients
The purpose of this adaptive trial is to compare the progression-free survival of participants with metastatic rectal carcinoma when treated with intravenous (IV) dalotuzumab (MK-0646) + irinotecan therapy relative to participants treated with IV cet...
NCT01243762
Phase 1
Completed
47 patients
This is an open-label, two-part study to evaluate the safety and tolerability of combination treatment with dalotuzumab + MK-2206, dalotuzumab + MK-0752, or dalotuzumab + ridaforolimus (MK-8669). Part 1 of the study will determine the dose-limiting t...
NCT00614393
Phase 2
Completed
558 patients
Medications:
Cetuximab
Dalotuzumab
This study will compare the safety and efficacy of dalotuzumab (MK-0646) in combination with cetuximab and irinotecan in treating participants with wild type KRAS (wtKRAS) metastatic colorectal cancer (CRC) compared to cetuximab and irinotecan alone....